IOVA250509P4000
- 0.60
- -0.34-36.17%
Iovance Biotherapeutics Newsroom
Earnings Preview: IOVA to Report Financial Results Post-market on May 08
Iovance Biotherapeutics, Inc. to Report First Quarter 2025 Financial Results and Corporate Updates on May 8, 2025
When Will Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Become Profitable?
$IOVA Stock Is up 7% Today. Here's What We See in Our Data.
Iovance Biotherapeutics to Present Pre-Clinical and Five-Year Outcomes Data at 2025 AACR and ASCO Annual Meetings
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses
Iovance Biotherapeutics Is Maintained at Buy by Goldman Sachs
Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $16
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $5
Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)
Barclays Maintains Overweight on Iovance Biotherapeutics, Lowers Price Target to $5
Institutional Investors May Adopt Severe Steps After Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Latest 8.3% Drop Adds to a Year Losses
Express News | Traws Pharma Inc - Iain Dukes to Become Interim CEO
Express News | Traws Pharma Inc - Werner Cautreels to Retire as CEO, Remain as Board Member
Traws Pharma Announces Management Updates
Top 3 Health Care Stocks That Are Set To Fly This Month
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket?
Express News | Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Stifel Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $18